TriangleNCT01085214 · OUTCOME
Duration of Response
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEAN
- Unit
- months
- Interval / dispersion
- Full Range
- Time frame
- From response to disease progression or death, assessed up to 2 years
What was measured
Mean duration of response in months. Estimated using the method of Kaplan-Meier.
Analysis population: All participants with response
Groups in this outcome
AZD6244 (Selumetinib) Treatment
Participants received AZD6244 (Selumetinib) orally (PO) twice a day (BID) on days 1-28. Courses repeated every 28 days in the absence of disease progression or unacceptable toxicity.
| Group | Source count |
|---|---|
| AZD6244 (Selumetinib) Treatment | 2 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| AZD6244 (Selumetinib) Treatment | 4.95 | Not reported | 4.83 | 5.06 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 4.83
- upper Limit
- 5.06
- value
- 4.95
- denoms
- counts
- group Id
- OG000
- value
- 2
- units
- Participants
- description
- Mean duration of response in months. Estimated using the method of Kaplan-Meier.
- dispersion Type
- Full Range
- groups
- description
- Participants received AZD6244 (Selumetinib) orally (PO) twice a day (BID) on days 1-28. Courses repeated every 28 days in the absence of disease progression or unacceptable toxicity.
- id
- OG000
- title
- AZD6244 (Selumetinib) Treatment
- param Type
- MEAN
- population Description
- All participants with response
- reporting Status
- POSTED
- time Frame
- From response to disease progression or death, assessed up to 2 years
- title
- Duration of Response
- type
- SECONDARY
- unit Of Measure
- months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice